β_(2)受体激动剂联合抗生素在慢性阻塞性肺病急性发作期的临床效果及安全性分析  

Clinical Effect and Safety Analysis ofβ_(2)Receptor Agonist Combined with Antibiotics in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

作　　者：甘建国 肖春雨 甘山花 江涛 GAN Jianguo;XIAO Chunyu;GAN Shanhua;JIANG Tao(The Third Department of Internal Medicine,Chongyi County People′s Hospital,Chongyi 341300,Jiangxi,China)

机构地区：[1]崇义县人民医院内三科,江西崇义341300

出　　处：《医学信息》2024年第23期109-112,共4页Journal of Medical Information

基　　金：2023年赣州市指导性科技计划项目(编号:2023DXNS4290)。

摘　　要：目的观察β_(2)受体激动剂联合抗生素在慢性阻塞性肺病急性发作期的临床效果及安全性。方法选取2022年1月-2023年3月我院收治的80例慢性阻塞性肺病急性发作期患者为研究对象,采用随机数字表法分为常规组和研究组,各40例。常规组采用抗生素治疗,研究组在常规组基础上联合β_(2)受体激动剂治疗,比较两组临床效果、6 min步行距离、呼吸困难分级评分、肺功能指标[1秒用力呼气容积(FEV_(1))、第一秒用力呼气容积占用力肺活量的比值(FEV_(1)/FVC)]、血气指标[动脉血二氧化碳分压(PaCO_(2))、动脉血氧分压(PaO_(2))],以及不良反应发生率。结果研究组治疗总有效率为95.00%,高于常规组的87.50%(P<0.05);研究组6 min步行距离、呼吸困难评分、FEV_(1)、FEV_(1)/FVC、PaO_(2)、PaCO_(2)均优于常规组(P<0.05);研究组不良反应发生率为7.50%,与常规组的10.00%比较,差异无统计学意义(P>0.05)。结论β_(2)受体激动剂联合抗生素在慢性阻塞性肺病急性发作期具有确切的效果,可降低患者呼吸困难评分,提高治疗有效率,增大6 min步行距离,改善肺功能和血气指标,且不增加临床不良反应发生率,值得临床加以应用。Objective To observe the clinical effect and safety ofβ_(2)receptor agonist combined with antibiotics in acute exacerbation of chronic obstructive pulmonary disease.Methods During January,2022 and March,2023,80 patients with acute exacerbation of chronic obstructive pulmonary disease admitted to our hospital were collected,and grouped by random number table method,while 40 patients were enrolled in the routine group and 40 patients were enrolled in the research group.Antibiotics was used for treatment in the routine group,while the research group was addedβ_(2)receptor agonist on the basis of the method which was carry out in the routine group.Results In comparison with the routine group,the research group was observed to have a higher total effective rate(P<0.05).Compared with the patients in the routine group after the treatment,6-minute walking distance,dyspnea grading scores,and FEV_(1),FEV_(1)/FVC,PaO_(2),PaCO_(2)level in the research group were significantly superior to the routine group(P<0.05).The incidence of adverse reactions in the research group was 7.50%,which was compared with 10.00%in the routine group,the difference was not statistically significant(P>0.05).Conclusionβ_(2)receptor agonist combined with antibiotics has a definite effect in the acute exacerbation of chronic obstructive pulmonary disease,which can reduce the dyspnea score of patients,improve the treatment efficiency,increase the 6-minute walking distance,improve lung function and blood gas index,and do not increase the incidence of clinical adverse reactions.It is worthy of clinical application.

关 键 词：β_(2)受体激动剂 抗生素 慢性阻塞性肺病 急性发作期 安全性 

分 类 号：R563.9[医药卫生—呼吸系统]